Sugi Predict

Sugi Predict / Compounds / SCHEMBL1454772

SCHEMBL1454772

SCHEMBL1454772

O=C1Nc2ccc(Cl)cc2C1=Cc1ccc(N2CCOCC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 3/20 0.71
▸ LRRK2 Q5S007 5/20 0.67
▸ PSEN1 P49768 2/20 0.67
▸ PSEN2 P49810 2/20 0.67
▸ APH1B Q8WW43 2/20 0.67
▸ NCSTN Q92542 2/20 0.67
▸ APH1A Q96BI3 2/20 0.67
▸ PSENEN Q9NZ42 2/20 0.67
▸ FLT3 P36888 1/20 0.67
▸ KDM4E B2RXH2 1/20 0.62
▸ ALDH1A1 P00352 1/20 0.62
▸ MAPT P10636 1/20 0.62
▸ ERBB2 P04626 2/20 0.56
▸ RET P07949 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1454770 1.00 PDGFRB (0.71) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL14519131 0.91 ERBB2 (0.68) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL5702054 0.88 LRRK2 (0.62) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL5469108 0.86 PDGFRB (0.77) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL5473127 0.86 PDGFRB (0.77) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL4996134 0.84 LRRK2 (0.52) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL4996140 0.84 LRRK2 (0.52) PDGFRBLRRK2PSEN1PSEN2APH1B
SCHEMBL1452713 0.83 PDGFRB (1.00) PDGFRBFLT3KDM4EALDH1A1MAPT
SCHEMBL1452716 0.83 PDGFRB (1.00) PDGFRBFLT3KDM4EALDH1A1MAPT
SCHEMBL5477805 0.82 LRRK2 (0.83) PDGFRBLRRK2PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5886020-A MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION SUGEN, INC. (US) 1999-03-23 — — US claimed
US-20110190492-A1 DIAGNOSTIC PROBE FOR CONFORMATION DISEASE TOHOKU UNIVERSITY (JP) 2011-08-04 — — US disclosed
US-7910579-B2 Benzoxazole derivatives TOHOKU UNIVERSITY (JP) 2011-03-22 — — US disclosed
US-20100021385-A1 BENZOXAZOLE DERIVATIVES TOHOKU UNIVERSITY (JP) 2010-01-28 — — US disclosed
EP-2103611-A1 BENZOXAZOLE DERIVATIVES Tohoku University (JP) 2009-09-23 — — EP disclosed
US-20090185975-A1 DIAGNOSTIC PROBE FOR CONFORMATION DISEASE TOHOKU UNIVERSITY (JP) 2009-07-23 — — US disclosed
EP-1967517-A1 PROBE FOR DIAGNOSIS OF CONFORMATIONAL DISEASE TOHOKU UNIVERSITY (JP) 2008-09-10 — — EP disclosed
CN-1268333-C Indolinone compounds for the treatment of disease SUGEN INC (US) 2006-08-09 — — CN disclosed
US-6906093-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2005-06-14 — — US disclosed
US-20030176487-A1 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease SUGEN, INC. 2003-09-18 — — US disclosed
US-6225335-B1 MODULATES TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; FOR THERAPY OF CANCER, ATHEROSCLEROSIS, ARTHRITIS AND RESTENOSIS AND METABOLIC DISEASES SUCH AS DIABETES SUGEN, INC. 2001-05-01 — — US disclosed
EP-0934931-A2 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators Sugen, Inc. (US) 1999-08-11 — — EP disclosed
US-5886020-A MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION SUGEN, INC. (US) 1999-03-23 — — US disclosed
US-5883113-A TYROSINE KINASE INHIBITORS; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGENTS; DIABETES, ARTHRITIS, RESTENOSIS, ATHEROSCLEROSIS SUGEN, INC. (US) 1999-03-16 — — US disclosed
US-5883116-A ANTITUMOR AGENTS AND ENZYME INHIBITORS SUGEN, INC. (US) 1999-03-16 — — US disclosed
US-5834504-A MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION SUGEN, INC. (US) 1998-11-10 — — US disclosed
EP-0769947-A4 INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE SUGEN INC (US) 1998-09-30 — — EP disclosed
CN-1155838-A Indolinone compounds for the treatment of disease SUGEN INC (US) 1997-07-30 — — CN disclosed
EP-0769947-A1 INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE Sugen, Inc. (US) 1997-05-02 — — EP disclosed
WO-1996040116-A1 INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE SUGEN, INC. (US) 1996-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176487-A1 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease ERBB2, MKI67, ABL1 PDGFRB 325/4885LRRK2 641/4885PSEN1 2640/4885
US-20090185975-A1 DIAGNOSTIC PROBE FOR CONFORMATION DISEASE TARDBP, LMNA, PMP22 PDGFRB 4037/4885LRRK2 3823/4885PSEN1 21/4885
US-20100021385-A1 BENZOXAZOLE DERIVATIVES CBX7, KIT, BMX PDGFRB 3651/4885LRRK2 4616/4885PSEN1 1170/4885
US-20110190492-A1 DIAGNOSTIC PROBE FOR CONFORMATION DISEASE TARDBP, LMNA, PMP22 PDGFRB 4037/4885LRRK2 3823/4885PSEN1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.